JP2024540922A5 - - Google Patents
Info
- Publication number
- JP2024540922A5 JP2024540922A5 JP2024523525A JP2024523525A JP2024540922A5 JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5 JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257073P | 2021-10-18 | 2021-10-18 | |
| US63/257,073 | 2021-10-18 | ||
| PCT/EP2022/078989 WO2023066941A1 (en) | 2021-10-18 | 2022-10-18 | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540922A JP2024540922A (ja) | 2024-11-06 |
| JPWO2023066941A5 JPWO2023066941A5 (https=) | 2025-10-27 |
| JP2024540922A5 true JP2024540922A5 (https=) | 2025-10-27 |
Family
ID=84359608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523525A Pending JP2024540922A (ja) | 2021-10-18 | 2022-10-18 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250066382A1 (https=) |
| EP (1) | EP4419530A1 (https=) |
| JP (1) | JP2024540922A (https=) |
| CN (1) | CN118451082A (https=) |
| WO (1) | WO2023066941A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| US11306104B2 (en) * | 2018-03-14 | 2022-04-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of Relugolix |
| WO2021069700A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
-
2022
- 2022-10-18 JP JP2024523525A patent/JP2024540922A/ja active Pending
- 2022-10-18 WO PCT/EP2022/078989 patent/WO2023066941A1/en not_active Ceased
- 2022-10-18 EP EP22805826.9A patent/EP4419530A1/en active Pending
- 2022-10-18 CN CN202280069988.XA patent/CN118451082A/zh active Pending
-
2024
- 2024-04-16 US US18/636,642 patent/US20250066382A1/en active Pending